Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil

American Journal of Ophthalmology

Volumn 105, Issue 2, 1988, Pages 155-159

  Abelson, Mark B ^a,b   Mitchell Gilbert, C ^a,b   Smith, Lisa M ^a,b  

^a Eye Research Institute   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VERAPAMIL;

DRUG THERAPY; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NORMAL HUMAN; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; MIDDLE AGE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; VERAPAMIL;

EID: 0023931674     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9394(88)90179-1     Document Type: Article

References (14)

1. The calcium antagonist, mechanism of action and pharmacologic effects
2. The physiology of aqueous humor formation
3. The effect of a calcium-channel blocking agent on intraocular pressure
4. Elevation of intraocular pressure by calcium channel blockers
5. Calcium entry blockers Uses and implications for anesthesiologists
6. New directions in the use of calcium channel blockers
7. Functional modulation of cell coupling. Evidence for a calmodulin-driven channel gate
8. An electrophysiologic study of rabbit ciliary epithelium
9. A mechanism for the control of aqueous humor formation
10. The Expert Committee of the World Health Organization on classification of calcium antagonists. The viewpoint of the raporteur
11. Effects of topical bupranolol hydrochloride on the intraocular pressure
12. Propranolol. An ocular hypotensive agent
13. Differences of adrenal stress control mechanisms in subjects with glaucoma and normal subjects. Effect of vasopressin and pyrogen
14. Neural control of intraocular pressure